HARVARD BIOSCIENCE INC
For the period ended Dec 31, 2023. Filed Mar 7, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 7, 2024
HBIO$9.09+8.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
HARVARD BIOSCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| December 31, | ||
|---|---|---|
| 2023 | 2022 | |
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $4,283 | $4,508 |
| Accounts receivable, net | 16,099 | 16,705 |
| Inventories | 24,716 | 26,439 |
| Other current assets | 3,940 | 3,472 |
| Total current assets | 49,038 | 51,124 |
| Property, plant and equipment, net | 3,981 | 3,366 |
| Operating lease right-of-use assets | 4,773 | 5,816 |
| Goodwill | 57,065 | 56,260 |
| Intangible assets, net | 16,036 | 21,014 |
| Other long-term assets | 6,473 | 7,780 |
| Total assets | $137,366 | $145,360 |
| Liabilities and Stockholders' Equity | ||
| Current liabilities: | ||
| Current portion of long-term debt | $5,859 | $3,811 |
| Current portion of operating lease liabilities | 1,416 | 2,135 |
| Accounts payable | 5,554 | 6,447 |
| Contract liabilities | 4,508 | 3,370 |
| Other current liabilities | 9,205 | 7,486 |
| Total current liabilities | 26,542 | 23,249 |
| Long-term debt, net | 30,704 | 43,013 |
| Deferred tax liability | 776 | 590 |
| Operating lease liabilities | 4,794 | 5,282 |
| Other long-term liabilities | 1,476 | 1,006 |
| Total liabilities | 64,292 | 73,140 |
| Stockholders' equity: | ||
| Preferred stock, par value $0.01 per share, 5,000,000 shares authorized | - | - |
| Common stock, par value $0.01 per share, 80,000,000 shares authorized: 43,394,509 shares issued and outstanding at December 31, 2023; 42,081,707 shares issued and outstanding at December 31, 2022 | 434 | 454 |
| Additional paid-in-capital | 232,435 | 229,008 |
| Accumulated deficit | (145,605) | (142,190) |
| Accumulated other comprehensive loss | (14,190) | (15,052) |
| Total stockholders' equity | 73,074 | 72,220 |
| Total liabilities and stockholders' equity | $137,366 | $145,360 |
See accompanying notes to condensed consolidated financial statements.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.